California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

Tech Talk for Tuesday September 26th 2017

  Observations Russell 2000 Index reaches an all-time high. Energy stocks on both sides of the border, led by oil service stocks were the strongest sector. A move by WTI Crude Oil above $52.00 per barrel also helped the sector. S&P Technology Index led the U.S. equity market...

Craft growers, dispensaries part of conversation at UBCM

‘Craft’ cannabis and a mixed public and private retail model were two of the main topics of the morning at the Union of BC Municipalities’ three hour session on legal cannabis in British Columbia, which took place this Monday at the Fairmont Hotel in downtown Vancouver. Th...

Trade War on the Horizon?

Two actions took place at the end of last week which heighten concerns that a trade war with China could be ever more likely.  First, there was the preliminary decision in the solar panels 201 case.  Then, we had the additional sanctions imposed by the President on North Korea...

Product Review: Santa Cruz Shredder

The grinder uses anodized metal and a unique tooth design to improve upon typical grinder design. Santa Cruz Shredder has revolutionized the design and durability of consumer and professional grade cannabis grinders. Their secret? Questioning the basics of what makes a grinder....

BC announces steps in cannabis legalization plans

Today, Mike Farnworth, BC’s Solicitor General and Minister of Public Safety, announced the creation of a joint committee on cannabis regulation with BC’s municipalities. This gives municipalities a more active and collaborative role in the development of the cannabis regul...

Hawaii becomes 1st state to create cashless solution for cannabis industry

On September 12th, Hawaii’s governor, David Ige, announced the creation of a cashless financial institution that finally allows the Hawaiian cannabis industry to go cashless. This breaks the industry’s reliance on cash-only transactions, putting the cannabis industry at the ...

What’s the Deal With All This Light Dep Cannabis?

Light deprivation isn’t a new cultivation technique, but there’s been a pronounced spike in its use by NorCal growers over the past year, leading to a flood of “light dep” bud on the market. If you’ve been buying cannabis recently — particularly on the Pacific Coast...

Tech Talk for Monday September 25th 2017

Pre-opening Comments for Monday September 25th U.S. equity index futures were lower this morning. S&P 500 futures were down 3 points in pre-opening trade. The DAX Index gained 0.2% after preliminary results from Germany’s federal election were released. DR Horton dropped $1....

Why rising rates don’t have to be alarming for income investors

Bonds serve a crucial role in helping investors reach their investment goals. They generate income, provide a measure of principal protection and can mitigate volatility. While bonds can help stabilize a portfolio, they are not without risks. Bond investors may worry about risin...

Dividend All-Stars 2018

.canadas-best-credit-cards-2017-hed{margin-bottom:1em;max-width:100%}@media (max-width: 991px){a.flex-item{width:93%}}@media (min-width: 992px){.canadas-best-credit-cards-2017-links{display:flex;flex-direction:row;flex-wrap:nowrap;justify-content:space-between;align-content:spac...